1012341-54-6

Basic information

• Product Name: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
• Synonyms: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid;LCZ 696 Impurity F;Sacubitril Impurity 1;LCZ704;(2S,4R)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid;LCZ-696 Impurity 18;LCZ-696 Impurity 35;(αS,γR)-γ-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-methyl-[1,1-biphenyl]-4-pentanoic Acid
• CAS NO: 1012341-54-6
• Molecular Formula: C23H29NO4
• Molecular Weight: 383.48066
• Product Categories: LCZ696
• Mol File: 1012341-54-6.mol

Chemical Properties

• Boiling Point: 582.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.115±0.06 g/cm3(Predicted)
• PKA: 4?+-.0.23(Predicted)
• CAS DataBase Reference: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid(1012341-54-6)
• EPA Substance Registry System: (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid(1012341-54-6)

Safety Data

• Hazardous Substances Data: 1012341-54-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure allows for the creation of novel drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid serves as a valuable building block for the creation of more complex molecules. Its versatility in reacting with other compounds makes it a useful component in the synthesis of various chemical products.
Used in Material Science:
(2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid can be utilized in the development of new materials with specific properties. Its incorporation into polymers or other materials may lead to enhanced characteristics such as improved strength, durability, or chemical resistance.
Used in Research and Development:
As a synthetic intermediate, (2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid is also used in research and development settings. Scientists and researchers can explore its potential applications and interactions with other compounds to discover new uses and advancements in various fields.

Upstream product

• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 1038924-71-8 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1038924-76-3 (3R,5S)-5-biphenyl-4-ylmethyl-3-methyl-2-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1174130-80-3 (R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylenepentanoic acid 
• 1174130-72-3 (R)-5-biphenyl-4-ylmethyl-3-methylene-2-oxo-pyrrolidine-1-carboxylic acid tert-butylester 
• 1361408-16-3 (Z)-(R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid 
• 1361408-15-2 (R)-5-biphenyl-4-ylmethyl-3-methyl-2-oxo-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester 
• 149709-61-5 (2S,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid ethyl ester 
• 70642-86-3 N-(tert-butoxycarbonyl)-D-tyrosine 
• 929872-80-0 tert-butyl (R)-3-(4-hydroxyphenyl)-1-[methoxy(methyl)amino]-1-oxopropan-2-ylcarbamate 
• 98-80-6 phenylboronic acid 
• 79561-82-3 (2R)-3-(4-bromophenyl)-2-[[(tert-butoxy)carbonyl]amino]propanoic acid 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 

Downstream Products

• 1038924-71-8 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid hydrochloride 
• 149709-60-4 ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate 
• 1174130-83-6 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid triethylammonium salt 
• 1174131-27-1 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid methyl ester 
• 1174131-28-2 (2S,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid methyl ester 
• 1174130-82-5 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid diisopropylethylammonium salt 
• 149709-61-5 (2S,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid ethyl ester 
• 1174130-84-7 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid sodium salt 
• 1257266-74-2 (2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methyl-pentanoic acid benzyl ester 
• 1257265-30-7 6-((1S,3R)-3-benzyloxycarbonyl-1-biphenyl-4-ylmethylbutylcarbamoyl)-4-oxo-4H-pyran-2-carboxylic acid 
• 1257265-29-4 6-((1S,3R)-1-biphenyl-4-ylmethyl-3-carboxybutylcarbamoyl)-4-oxo-4H-pyran-2-carboxylic acid 
• 1257266-14-0 (2R,4S)-5-biphenyl-4-yl-4-isocyanato-2-methylpentanoic acid benzyl ester 
• 1257265-46-5 1-((1S,3R)-3-benzyloxycarbonyl-1-biphenyl-4-ylmethylbutylcarbamoyl)-1H-pyrazole-3-carboxylic acid 
• 1257265-45-4 1-((1S,3R)-1-biphenyl-4-ylmethyl-3-carboxybutylcarbamoyl)-1H-pyrazole-3-carboxylic acid 

Relevant articles and documents

Method for preparing chiral biaryl substituted 4-amino-butyric acid and derivative thereof

The invention discloses a method for preparing chiral biaryl substituted 4-amino-butyric acid and a derivative thereof. The method belongs to chiral catalytic hydrogenation reaction, and has the advantages of high conversion rate, good selectivity, simplicity in operation, low catalyst dosage, low production cost, suitability for industrial large-scale production and the like.

Substituted ferrocenyl diphosphine homogeneous catalyst ligand

The invention provides a substituted ferrocenyl diphosphine homogeneous catalyst ligand formula I compound. Further, the formula I compound is a metal complex ligand of a homogeneous hydrogenation catalyst. The catalyst ligand is easy to synthesize, convenient to post-treat and easy for industrial production, and very high activity, productivity and enantioselectivity can be obtained by using thecatalyst. The compound is shown in the specification.

Preparation method of sacubitril valsartan sodium

The invention provides a preparation method of sacubitril valsartan sodium, and belongs to the field of medical chemistry. The preparation method comprises the following steps: by using a compound S309A03 as a raw material, carrying out hydrogenation reaction to generate a compound BPA08, reacting the compound BPA08 in ethanol to generate a compound SAC01, reacting the compound SAC01 with succinicanhydride to generate a compound SAC02, optionally reacting the compound SAC02 with sodium hydroxide, and reacting the compound SAC03 with calcium chloride to generate a compound SAC04; and subjecting the compound SAC04 to acid treatment to obtain a compound YJX01, and enabling the compound YJX01 to react with VST in a single solvent in the presence of sodium hydroxide to prepare the compound YJX02. The preparation method disclosed by the invention is simple to operate, the time required by the process is reduced, the total yield of the process route is greatly improved, an unexpected technical effect is obtained, impurities in the process are removed, and a product with higher purity is obtained. The method has mild process conditions and easily available raw materials, and is suitable for industrial amplification.

OXA-SPIRODIPHOSPHINE LIGAND AND METHOD FOR ASYMMETRIC HYDROGENATION OF alpha, beta-UNSATURATED CARBOXYLIC ACIDS

The present invention provides an oxa-spirodiphosphine ligand having a structure of general Formula (I) below: wherein in general Formula (I), R1, R2, R3 and R4 are the same, and are alkyl, alkoxy, aryl, aryloxy

Optimization and process improvement for LCZ696 by employing quality by design (QbD) principles

Efforts toward optimization and improvement for the synthesis of LCZ696 employing design of experiment (DoE) principles are described. By increasing the purity of intermediates and mitigating impurity risk during each step, a telescoped process was developed via removal of isolation of intermediates with the overall yield increased by 28.5% from 45.3% to 73.8%. And the whole production cycle was also shortened from 12 days to 7 days with simplified operations and restored process greenness. Meanwhile, the corresponding impurity profile was thus studied in detail and well documented.

Preparation method of sacubitril intermediate

The invention relates to a preparation method of a sacubitril intermediate, and belongs to the technical field of drug intermediate synthesis. The problems that existing operation is large in difficulty and not easy to control are solved. In the presence of a nickel salt catalyst and (R,R)-(-)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine, a compound (E)-(R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid represented by formula II and ammonium formate are mixed in an alcohol solvent and undergo an asymmetric reduction reaction to obtain the corresponding sacubitril intermediate compound represented by formula I. The method does not need to be required to be in an inert atmosphere during production, and is more beneficial to operation. The cost of the raw materials is effectively reduced, and the effect of high yield can still be achieved.

Synthetic method for sacubitril intermediate

The invention relates to a synthetic method for a sacubitril intermediate and aims at solving the technical problems of expensive reagents, harsh reaction conditions, low yield and the like of the existing synthetic method. The synthetic method provided b

Oxa-spiral diphosphine ligand and application thereof in alpha, beta-unsaturated carboxylic acid asymmetric hydrogenation

The invention provides an oxa-spiral diphosphine ligand. The oxa-spiral diphosphine ligand has a structure shown by a general formula (I) as shown in description, wherein R1, R2, R3 and R4 in the general formula (I) are same and are alkyl, alkoxy, aryl, aroxyl, or hydrogen atoms; R1, R2, R3 and R4 comprise forms of ring formation, non-ring formation, any two ring formation or multiple-ring formation between pairs; R5 and R6 are alkyl, aryl or hydrogen atoms; and R7 and R8 are alkyl or benzyl or aryl. The invention further provides application of the oxa-spiral diphosphine ligand O-SDP in the alpha, beta-unsaturated carboxylic acid asymmetric hydrogenation. A complex of the oxa-spiral diphosphine ligand O-SDP and ruthenium has excellent activity and enantioselectivity in the asymmetric hydrogenation of the alpha, beta-unsaturated carboxylic acid in multiple types, and a chiral carboxylic acid product is obtained with the enantioselectivity being up to 99%. The synthesis method can be applied to the construction of a core skeleton of chemical molecules with important activity, wherein the chemical molecules comprise Paroxetine, Femoxetine, nipecotic acid and Sacubitril.

Synthesis, Isolation, and Analysis of Stereoisomers of Sacubitril

An efficient industrial synthetic process for sacubitril has been developed. Stereoisomers derived from sacubitril and its crucial intermediate have been synthesized, isolated, and characterized for quality control. These stereoisomers were characterized by spectral data (MS and NMR) and used as reference standards for development of HPLC methods.

Method for preparing sacubitril and intermediate thereof

The invention provides a method for preparing sacubitril and an intermediate thereof and belongs to the field of medicine synthesis. The method comprises the following steps: by taking a compound I asa raw material, carrying out an asymmetric reduction reaction under the action of a chiral metallic catalyst so as to obtain an intermediate; finally carrying out a simple synthesis step, thereby obtaining a target product sacubitril. The method is short in synthesis route, easy to implement, high in reaction yield, good in diastereoselectivity, and capable of avoiding relatively tedious aftertreatment steps, and reducing the production cost of the sacubitril while the production efficiency of the sacubitril is improved.